Verastem Advances VS-7375 Into Phase 2 Pancreatic Trial
I'm LongbridgeAI, I can summarize articles.Verastem (VSTM) advanced its KRAS G12D inhibitor VS-7375 into a Phase 2 registration-directed trial for metastatic pancreatic cancer. The company also reported encouraging Phase 1b/2a data for avutometinib plus defactinib combined with chemotherapy, showing high survival and response rates. Despite positive pipeline updates, analyst sentiment remains mixed due to weak financials and technical indicators.
Verastem ( (VSTM) ) has issued an announcement.
On June 17, 2026, Verastem reported updated Phase 1b/2a data from its RAMP 205 trial testing avutometinib plus defactinib with gemcitabine and nab-paclitaxel as first-line therapy for metastatic pancreatic ductal adenocarcinoma. Among 29 patients treated at the recommended Phase 2 dose and followed for a median 9.8 months, the regimen showed an 86% six-month overall survival rate, 68% six-month progression-free survival, a 52% confirmed objective response rate, and tumor shrinkage in 83% of patients, with no new safety signals and nine patients still on treatment as of the June 5, 2026 cutoff.
The day before, on June 16, 2026, Verastem began dosing the first patient in TARGET-D 201, a Phase 2 registration-directed study of VS-7375 at 900 mg daily, both as a monotherapy and combined with cetuximab, in second-line KRAS G12D-mutated metastatic pancreatic cancer. Together, the encouraging pancreatic data for the avutometinib–defactinib–chemotherapy combination and the advancement of VS-7375 into a pivotal-style program underscore Verastem’s bid to deepen its presence in KRAS-driven pancreatic cancer and could strengthen its competitive position if these investigational approaches ultimately translate into improved outcomes in this high-mortality indication.
The most recent analyst rating on (VSTM) stock is a Buy
with a $14.00 price target.
To see the full list of analyst forecasts on Verastem stock,
see the VSTM Stock Forecast page.
Spark’s Take on VSTM Stock
According to Spark, TipRanks’ AI Analyst, VSTM is a Neutral.
The score is held down primarily by weak financials—large ongoing operating losses and substantial cash burn—alongside a clearly bearish technical setup with the stock trading below key moving averages. Offsetting factors include encouraging earnings-call updates on revenue trajectory, pipeline advancement, and stated cash runway into H1 2027, while valuation provides limited support due to negative earnings and no dividend yield data.
To see Spark’s full report on VSTM stock,
click here.
More about Verastem
Verastem Oncology, listed on Nasdaq as VSTM, is a biopharmaceutical company focused on developing targeted therapies for cancers driven by the RAS/MAPK pathway. Its lead assets include avutometinib and defactinib, marketed together as the AVMAPKI FAKZYNJA co-pack for KRAS-mutated recurrent low-grade serous ovarian cancer under accelerated U.S. approval, and it is expanding development into pancreatic and other RAS/MAPK-driven tumors.
The company’s pipeline also features VS-7375, an investigational oral KRAS G12D (ON/OFF) inhibitor aimed at tumors harboring this prevalent and poor-prognosis mutation. Supported in part by a PanCAN Therapeutic Accelerator Award, Verastem is positioning itself within the competitive oncology space by targeting difficult-to-treat metastatic solid tumors and exploring combination regimens with standard chemotherapy and biologics.
Average Trading Volume: 2,291,494
Technical Sentiment Signal: Sell
Current Market Cap: $351.5M
Learn more about VSTM stock on TipRanks’ Stock Analysis page.